MEANING OF HbA1c IN THE DIAGNOSIS AND SCREENING OF DIABETES MELLITUS

Authors

  • Mire Spasov Faculty of Medical Science, University „Goce Delcev“- Stip, Republic of North Macedonia
  • Hristijan Spasov Faculty of Natural Sciences and Mathematics, University „St. Cyril and Methodius“- Skopje, Republic of North Macedonia

Keywords:

hemoglobin A1c, insulin, glycolysis, Diabetes mellitus, Glucophage

Abstract

The main functional protein of erythrocytes is hemoglobin, which is not normally found in plasma, but during hemolysis, erythrocytes break down, it comes out of them and binds to the haptaglobin protein. Hemoglobin is a chromoprotein found in erythrocytes and carries out the transport of oxygen from the lungs to the tissues and the transport of carbon dioxide from the tissues to the lungs. These gases are loosely bound to the iron in the composition of heme as the non-protein component of hemoglobin, which also contains the protein component globin. In erythrocytes, there is also hemoglobin A1c in a certain amount, which is formed through non-enzymatic glycolysis of valine residues from the N-terminal end of the β-chain of hemoglobin A. It is created in pathological cases when the glucose in the blood has high concentrations, that is, the excess of glucose binds to the hemoglobin. Glycosylated HbA1c is of great importance for monitoring treatment and therapy in patients with diabetes mellitus, because its concentration is proportional to the concentration of glucose and in the long term, within three months, because HbA1c does not break down and remains present in the blood until erythrocytes are destroyed. The purpose of the research is to prove the significance of determining the concentration of HbA1c in monitoring diabetes mellitus and keeping it under control. This is the most reliable method for detecting poor metabolic regulation of diabetes, especially in cases where it remains undetected for a long time, and blood glucose is tested once every 2–3 months. The trials were conducted in young female patients aged 25 to 35 years with previously confirmed hyperglycemia. The patients were divided into three groups, a control group of patients with a normal level of glycemia in the circulation (n=30), a group of patients with diagnosed hyperglycemia (n=30), a group of patients treated with therapy to reduce the level of glycemia in the blood with Glucophage, which acts on the basis of dopamine (n=30). HbA1c is determined by an immunochemical inhibitory method that uses two reagents, one of which contains mouse antibodies to HbA1c applied to latex particles. The second reagent contains parts of HbA1c as antigens applied to agglutinators. The measurements were performed on an automated biochemical analyzer ARCHITECT 4000. The obtained results showed that patients diagnosed with diabetes mellitus have significantly increased results for the concentration of glycemia compared to patients from the control group whose results are within normal glucose values. The group of patients treated with therapy to reduce the level of glucose in the blood, that is, with Glucophage, have evidently reduced values for the level of glucose to a level close to the control group. There is a visible effect of Glucophage therapy in reducing the concentration of glucose in the blood. The drug reduces the concentration of glucose in the blood to normal values, that is, it regulates the level of sugar in the blood in such a way that it reduces the breakdown of glycogen from the liver to glucose, and increases the use of glucose in muscle cells. With the application of antidiabetic therapy with Glucophage, the negative effect of hyperglycemia is removed. In conditions of hyperglycemia, the concentration of glucose significantly increases compared to the control group, and in the treated group of patients, the level of glucose significantly decreases to values close to the control group of patients.

References

American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S73-S84.

Bunn, H.F., Haney, D.N., Kamin, S., Gabbay, K.H,, Gallop, P.M. (1976). The biosynsthesis of human hemoglobin A1c. J Clin Invest. 57:1652-9.

Gilstrap, L.G., Chernew, M.E,, Nguyen, C.A,, Alam, S., Bai, B., McWilliams, J.M., Landon, B.E., Landrum, M.B. (2019). Association Between Clinical Practice Group Adherence to Quality Measures and Adverse Outcomes Among Adult Patients With Diabetes. JAMA Netw Open. Aug 02;2(8):e199139.

Gibb, I., Parnham, A., FonfrÒde, M., Lecock, F. (1999). Multicenterevaluation of Tosoh glycohemoglobin analyzer. Clin. Chem. 45: 1833’ 41.

Geistanger, A., et all. (2008). Statistical methods for monitoring the relationship between the designated comparasion methods in the United States, Japan and Sweden. Clin. Chem. 54(8):1379-85.

Guo, W., Zhou, Q., Jia, Y., Xu, J. (2019). Increased Levels of Glycated Hemoglobin A1c and Iron Deficiency Anemia: A Review. Med Sci Monit. 25:8371-8378.

HbA1c in a new way Arhivirano na sajtu Wayback Machine (13. jul 2022) By the Swedish Diabetes Association. Retrieved mart 2011.

John, W.G. (2022). UK Department of Health Advisory Committee on Diabetes. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. Diabet Med 2012;29(11):1350-7

Kahn, R., Fonseca, V. (2019). Translating the A1c Assay. Diabetes Care. 31(8):1704-7.

Miedema, K. (2005). "Standardization of HbA1c and Optimal Range of Monitoring". Scandinavian Journal of Clinical and Laboratory Investigation. 240: 61–72.

Mortensen, H.B. (1983). Christophersen C. Glucosylation of human haemoglobin A in red blood cells studied in vivo: kinetics of the formation and dissociation of haemoglobin A1c. Clin Chem Acta. 134:317-26

Nathan, D.M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D. (2008). A1c-Derived Average Glucose Study Group. Translating the A1C assay intoestimated average glucose values. Diabetes Care. 31:1473–1478

Nathan, D.M. (2021). Realising the long-term promise of insulin therapy: the DCCT/EDIC study. Diabetologia. 64(5):1049-1058.

Niederau, C.M., Reinauer, H. (1998). Glycohemoglobins. In Thomas L ed. Clinical laboratory diagnostics. Use and assessment of clinical laboratory results. Frankfurt/Main: THBooks Verlagsgesellschaft mbH, 142-148.

Pilla, R., Palleti, S.K., Rayana, R., Skss, S.R., Abdul Razzack, A., Kalla, S. (2020). Glycated Haemoglobin (HbA1c) Variations in Nondiabetics With Nutritional Anemia. Cureus. 12(11):e11479.

Saboo, B., Kesavadev, J., Shankar, A., Krishna, M.B., Sheth, S., Patel, V., Krishnan, G. (2021). Time-in-range as a target in type 2 diabetes: An urgent need. Heliyon. 7(1):e05967.

Sacks, D.B. (1994). Glycated proteins. In: Burtis CA, Ashwood ER ed. Tietz textbook of clinical chemistry. Philadelphia: W.B. Saunders Company. 980’8.

Sidorenkov, Grigory., Haaijer-Ruskamp, Flora, M., De Zeeuw, Dick., Denig, Petra. (2011). „A Longitudinal Study Examining Adherence to Guidelines in Diabetes Care According to Different Definitions of AdequacyandTimeliness”. PLOSONE. 6 (9):e24278. Bibcode:2011PLoSO...624278S. PMC 3169586 . PMID 21931669. doi:10.1371/journal.pone.0024278

Talwar, D., Barr, B.B., Kesson, C.M., Robb, D.A. (1983). Determination of glycosylated adult and foetal haemoglobins by affinity chromatography. Clin Chim Acta 128: 61’ 67.

Trivelli, L.A., Ranney, H.M., Lai, H.T. (1971). Hemoglobin components in patients with diabetes mеllitus. N Engl J Med. 284: 353 ’7.

Downloads

Published

2023-12-10

How to Cite

Spasov, M., & Spasov, H. (2023). MEANING OF HbA1c IN THE DIAGNOSIS AND SCREENING OF DIABETES MELLITUS. KNOWLEDGE - International Journal , 61(4), 553–557. Retrieved from https://ikm.mk/ojs/index.php/kij/article/view/6451

Most read articles by the same author(s)

1 2 > >>